On Monday, Charles Schwab Corp (NYSE:SCHW)’s shares inclined 1.51% to $32.25.
The Charles Schwab Corporation released its Monthly Activity Report recently. Company highlights for the month of November 2015 comprise:
- Net new assets brought to the company by new and existing clients in November 2015 totaled $17.2 billion. November 2015 net new assets comprised of a $10.2 billion inflow related to a mutual fund clearing services client.
- Total client assets were $2.55 trillion as of month-end November, up 3% from November 2014 and up 1% contrast to October 2015.
- Average interest-earning assets on the company’s balance sheet were a record $167.4 billion in November, up 18% from November 2014 and up 1% contrast to October 2015.
Commentary from the CFO
Joe Martinetto, Senior Executive Vice President and Chief Financial Officer, provides a review of company comments regarding the potential impact of rising interest rates on Schwab’s financial picture at: http://aboutschwab.com/investor-relations/cfo-commentary.
The Charles Schwab Corporation, through its auxiliaries, provides wealth administration, securities brokerage, banking, money administration, and financial advisory services. The company operates through two segments, Investor Services and Advisor Services.
IsoRay, Inc. (NYSEMKT:ISR)’s shares gained 3.92% to $1.06.
IsoRay Inc. (ISR), declared the recent publication of the peer-reviewed results of a study entitled: “Neurocognitive function and quality of life in patients with newly diagnosed metastasis after treatment with intra-operative cesium-131 brachytherapy: a prospective trial.”
Twenty-four patients with newly diagnosed metastasis to the brain were treated with Cs-131 brachytherapy seeds after surgical resection between 2010 and 2012. Study protocols required physician administered mini-mental status examinations (MMSE) and functional assessment of cancer brain therapy (FACT-Br) questionnaires to all patients before treatment, and again every 2 months for a 6 month period, with a final follow-up at 12 months. Results of the study suggest that surgical resection with intraoperative Cs-131 brachytherapy is able to “stabilize or improve NCF [neurocognitive function] for patients with metastatic brain tumors by improving control of brain tumors and avoiding the toxicity of WBRT [whole brain radiotherapy].”
The study was presented at ASTRO’s 56th Annual Meeting in San Francisco, CA, on September 16, 2014. The research paper was published online on December 9, 2015 in the Journal of Neuro-Oncology (Pham, Anthony, et. al., “Neurocognitive function and quality of life in patients with newly diagnosed brain metastasis after treatment with intra-operative cesium-131.
IsoRay, Inc. develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces Proxcelan Cesium-131 brachytherapy seeds for the treatment of prostate, lung, head and neck, colorectal, brain, pelvic/abdominal, and gynecological cancers, in addition to ocular melanoma.
At the end of Monday’s trade, AbbVie Inc (NYSE:ABBV)‘s shares surged 2.59% to $55.44.
AbbVie (ABBV), a global biopharmaceutical company, declared results from the Phase 3 RAY (MCL3001) trial, which showed IMBRUVICA® (ibrutinib) significantly prolonged progression-free survival (PFS; the primary endpoint) and improved overall response rates (ORR; a key secondary endpoint) in patients with relapsed or refractory mantle cell lymphoma (MCL), contrast with temsirolimus. Notably, IMBRUVICA was associated with a 57% reduction in the risk of progression or death with a median follow-up of 20 months. These data were published online in The Lancet recently and presented in an oral session at the 57th Annual American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL. IMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.
Mantle cell lymphoma is an aggressive form of blood cancer which arises from B cells, a type of white blood cell (lymphocyte) that originates in the bone marrow. MCL is more prevalent in men than women. The majority of patients are in their mid-60s at diagnosis and the median overall survival rate is three to four years.
IMBRUVICA significantly improved PFS as determined by an Independent Review Committee (IRC) contrast to treatment with temsirolimus, resulting in a reduction in the risk of disease progression or death by 57% after a median follow-up of 20 months (HR 0.43 [95% CI, 0.32-0.58; P
These findings are compriseent with results from previous single-arm Phase 2 studies evaluating the safety and efficacy of IMBRUVICA in patients with MCL.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
